---
layout: default
title: Diclofenac
parent: 僅模型預測 (L5)
nav_order: 170
evidence_level: L5
indication_count: 10
---

# Diclofenac
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Diclofenac: From Pain and Inflammation (NSAID) to Hypotrichosis Simplex of the Scalp

## One-Sentence Summary

Diclofenac is a widely used nonsteroidal anti-inflammatory drug (NSAID), pharmacologically indicated for pain, inflammation, and musculoskeletal conditions (formal SAHPRA-approved indication text is not available in this evidence pack, as the product is currently unregistered/not marketed in South Africa). The TxGNN model's top-ranked prediction is **Hypotrichosis Simplex of the Scalp**, with a very high similarity score (**99.69%**) but **zero supporting clinical trials and zero literature**. The evidence pack's own mechanistic analysis flags this result as a likely knowledge-graph embedding artefact rather than a biologically credible signal, and this report recommends **Hold**.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available from SAHPRA registration data (drug not currently marketed in South Africa); generally described in the pharmacological literature as an NSAID for pain and inflammation |
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 99.69% |
| Evidence Level | L5 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a Blocking/High-severity data gap in this evidence pack). Based on general pharmacological knowledge, Diclofenac is an NSAID that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis to produce anti-inflammatory, analgesic, and antipyretic effects. This mechanism underlies its established use in pain and inflammatory musculoskeletal conditions.

Hypotrichosis simplex of the scalp, however, is a rare hereditary hair-loss disorder caused by mutations in keratinization/hair-follicle genes such as *APCDD1* and *CDSN*. It is a structural/developmental disorder of the hair follicle, not an inflammatory or prostaglandin-mediated condition. The evidence pack's own mechanistic assessment explicitly states there is **no known biological relationship** between COX inhibition and this disease's pathophysiology, and notes that the unusually high TxGNN score is more likely a **false positive arising from knowledge-graph embedding** than a genuine pharmacological signal.

In short, this top-ranked prediction lacks mechanistic plausibility, and its high score should not be interpreted as clinical evidence. It is included here for transparency because it is the model's rank-1 output, but it does not currently meet the bar for further evaluation.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## South Africa Market Information

Diclofenac is currently **not marketed** in South Africa under this evidence pack's records, with **0 SAHPRA registrations** on file. No product-level registration data (registration number, product name, dosage form, approved indication) is available to list.

---

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

*(Note: this evidence pack flags a Blocking data gap — TFDA/SAHPRA label warnings and contraindications are not yet retrieved — which by itself is sufficient to prevent this candidate from advancing to a formal safety review.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- The top-ranked predicted indication (hypotrichosis simplex of the scalp) has no supporting clinical trials or literature, an L5 evidence level (model prediction only), and its own mechanistic rationale flags it as a probable false positive rather than a credible repurposing hypothesis.
- A Blocking data gap (missing SAHPRA label warnings/contraindications) independently prevents this candidate from entering safety evaluation, and the drug is not currently marketed in South Africa (0 registrations).

**To proceed, the following is needed:**
- SAHPRA-approved Professional Information (PI) — warnings, contraindications, and safety data (currently a Blocking data gap)
- Confirmed mechanism of action (MOA) documentation from DrugBank or equivalent source
- Independent biological/preclinical rationale connecting COX inhibition to hair-follicle keratinization pathways, if this candidate is to be pursued further
- **Note for reviewers:** a lower-ranked candidate in this same evidence pack, *Juvenile Idiopathic Arthritis* (rank 9, score 99.25%), has actual supporting clinical trial evidence (2 trials, including an NSAID-specific safety registry), a well-established mechanistic link (NSAIDs are guideline-recommended first-line symptomatic therapy for JIA), and a higher internal evidence level (L3, "Proceed with Guardrails"). This indication is mechanistically and clinically far more credible than the rank-1 score suggests and may warrant separate, prioritized evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

